Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | ATP4A | P20648 | 1/20 | 0.51 |
| ▸ | ATP4B | P51164 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509589 | 0.79 | RAB9A (0.63) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL6508538 | 0.78 | RAB9A (0.74) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL4101661 | 0.78 | LMNA (0.54) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL4101663 | 0.78 | LMNA (0.54) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL10388188 | 0.78 | LMNA (0.54) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL10501633 | 0.77 | ADORA2A (0.56) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL10501630 | 0.77 | ADORA2A (0.56) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL6507406 | 0.76 | RAB9A (0.52) | ADORA2ARAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4104981 | 0.75 | ADORA2A (0.55) | ADORA2ARAB9AHRH4MEN1KMT2A | |
| SCHEMBL4104983 | 0.75 | ADORA2A (0.55) | ADORA2ARAB9AHRH4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| WO-2004037166-A2 | THERAPEUTIC GUANIDINES | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | ADORA2A 3878/4885RAB9A 3313/4885HRH4 3509/4885 |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | ADORA2A 32/4885RAB9A 1031/4885HRH4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.